17495-12-4

Usage

Classification

Purine derivative

Structure

Contains a pyrimidine ring fused to an imidazole ring

Applications

Pharmaceutical Research: Utilized in drug development
Potential Therapeutic Uses:
Anticancer drug design and synthesis
Antiviral drug development
Investigation for treating neurological disorders
Enzyme inhibition studies

Versatility

Suitable for biological and pharmacological studies

Upstream product

• 72360-76-0 7-benzylguanosine 
• 100-39-0 benzyl bromide 
• 224317-32-2 (1'S,2'R,3'S,4'S)-9-<2,3-dihydroxy-4-(hydroxymethyl)cyclopentan-1-yl>guanine 
• 56025-86-6 7-benzyl-3-methylxanthine 
• 100-44-7 benzyl chloride 
• 61393-37-1 guanosine sodium salt 
• 6691-47-0 3-Methylxanthine potassium salt 
• 73-40-5 2-amino-1,9-dihydro-6H-purin-6-one 
• 17495-10-2 N²-acetyl-7-benzylguanine 
• 118-00-3 G 
• 961-07-9 2'-Deoxyguanosine 
• 56025-88-8 7-benzyl-2-chloro-1,7-dihydro-purin-6-one 

Downstream Products

• 73-40-5 guanine 
• 17495-10-2 N²-acetyl-7-benzylguanine 
• 56160-64-6 7-benzylxanthine 
• 454710-37-3 7-benzyl-3-((2-(trimethylsilyl)ethoxy)methyl)-1H-purine-2,6(3H,7H)-dione 
• 200487-26-9 3-isopropyl-7-benzyl-xanthine 
• 879-08-3 9-Ethylguanine 
• 5502-78-3 9-Methylguanine 

Relevant academic research and scientific papers

SYNTHESIS OF GUANINE FROM 3-METHYLXANTHINE

A new preparative method of obtaining guanine from 3-methylxanthine has been developed.

SUBSTITUTED XANTHINE DERIVATIVES

The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.

INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL

The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Rec

NOVEL SUBSTITUTED XANTHINE DERIVATIVES

The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

PURINONE DERIVATIVES AS HM74A AGONISTS

The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.

Easy preparative scale syntheses of labelled xanthines: Caffeine, theophylline and theobromine

Several easy preparative scale (0.5-1.5 g) syntheses of deuterium labelled caffeine, theophylline and theobromine are described. Some new selective syntheses of theophylline and theobromine have been developed. Labelled xanthines are of great interest in qualitative or quantitative isotope dilution-mass spectrometry, coupled with gas or liquid chromatography, currently performed in anti-doping and forensic laboratories. Copyright

Regioselective functionalization of guanine: Simple and practical synthesis of 7- and 9-alkylated guanines starting from guanosine

Reaction of N2-acetyl-9- and/or -7-benzylated guanines 8 and 12 with selected alkylating agents in 1-methyl-2-pyrrolidone at 120°C yielded the guaninium salts 9 and 13. The salts were consequently transformed by phase transfer hydrogenation into N7- and N9-isomers 10 and 14, respectively, in a highly regioselective manner. A convenient deoxygenation of both derivatives, achieved via the corresponding O6-arenesulfonates, into 2-aminopurine potential prodrugs was also established.

Process for producing purine derivatives

A process for preparing 7-benzylpurine derivatives is provided. An acetylpurine nucleoside is reacted with a benzyl halide to benzylate the 7-position of the purine base, and an acid is then added to the reaction mixture to hydrolyze the glycoside bond. The 7-benzylpurines may be used to prepare 9-substituted purine derivatives.

Effect of ionic state of 2'-deoxyguanosine and solvent on its aralkylation by benzyl bromide

To extend studies of the aralkylation of nucleic acid components under a variety of solvent conditions, we determined product distributions from the reactions of benzyl bromide with 2'-deoxyguanosine and the anion of 2'- deoxyguanosine in 2,2,2-trifluoroethanol (TFE) and compared these distributions with those from the reaction of the anion with benzyl bromide in N,N-dimethylacetamide (DMA). 7-Benzylguanine was the only benzylated product detected in the reaction with the neutral nucleoside in TFE. In striking contrast, the reaction of the anion of 2'-deoxyguanosine with benzyl bromide in TFE produced N2-benzyl-2'-deoxyguanosine in significant yield and with high selectivity. The reaction of the anion of 2'-deoxyguanosine with benzyl bromide in DMA produced products derived only from reaction at the 1- and/or 7-position of the nucleoside. The weakly nucleophilic but protic polar solvent TFE and the iminolate tautomeric form of the 2'-deoxyguanosine anion appear to be essential for benzylation at the exocyclic N2-position.